Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer (NCT05855200)
A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy Versus Standard of Care in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
🩺 Plain-English Summary (8th-Grade Level)
The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon cancer.
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — Tucson, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (266 Sites)
Showing the first 25 of 266 sites.
- GSK Investigational Site — Tucson, Arizona
- GSK Investigational Site — Los Angeles, California
- GSK Investigational Site — New Haven, Connecticut
- GSK Investigational Site — Washington D.C., District of Columbia
- GSK Investigational Site — Deerfield Beach, Florida
- GSK Investigational Site — Fort Lauderdale, Florida
- GSK Investigational Site — Marietta, Georgia
- GSK Investigational Site — Chicago, Illinois
- GSK Investigational Site — Chicago, Illinois
- GSK Investigational Site — Chicago, Illinois
- GSK Investigational Site — Naperville, Illinois
- GSK Investigational Site — Naperville, Illinois
- GSK Investigational Site — Westwood, Kansas
- GSK Investigational Site — Lexington, Kentucky
- GSK Investigational Site — Louisville, Kentucky
- GSK Investigational Site — Baton Rouge, Louisiana
- GSK Investigational Site — Bethesda, Maryland
- GSK Investigational Site — Ann Arbor, Michigan
- GSK Investigational Site — Detroit, Michigan
- GSK Investigational Site — Minneapolis, Minnesota
- GSK Investigational Site — Joplin, Missouri
- GSK Investigational Site — St Louis, Missouri
- GSK Investigational Site — St Louis, Missouri
- GSK Investigational Site — Grand Island, Nebraska
- GSK Investigational Site — Omaha, Nebraska
📞 Contact the Study Coordinator
Phone: (877) 379-3718
Email: GSKClinicalSupportHD@gsk.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Colonic Neoplasms
- Strategies for Optimizing a Mailed FIT Program in Appalachia — Columbus, Ohio
- Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas — Los Angeles, California
- Effects of Aerobic Exercise on Skeletal Muscle Remodeling in Colorectal Cancer — Orlando, Florida
- Adaptive Randomization of Aerobic Exercise During Chemotherapy in Colon Cancer — Oakland, California
Explore by condition: All Colonic Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.